Interferon-α-2a

Reactions 1181 - 8 Dec 2007 Interferon-α-2a Hypomanic mood in a child: case report A 10-year-old boy developed hypomanic mood while receiving interferon-α-2a for chronic hepatitis B. The boy received SC interferon-α-2a at a dose of 3 MIU three times weekly. About 30 days after the start of treatment, his parents noticed a change in his mood, with marked irritability and psychomotor agitation. He also showed excessive involvement in activities with a high risk of painful consequences. He had episodes of staring, closed eyes, loss of consciousness, thrashing and chaotic jerky movements of his trunk, limbs and head. Each episode lasted for about 10–20 minutes and recurred at intervals throughout the week. Postcritical arousal was slow and followed by irritability and headache. He was hyperactive, distracted, excessively talkative and had a decreased need for sleep. A mental status examination showed inflated self-esteem, increased speech rhythm and racing thoughts. He had pathological total scores on the Parent Child Behavior Checklist (CBCL) and the Multidimensional Anxiety Scale for Children (MASC). The boy received risperidone and cognitive-behavioural treatment. Interferon-α-2a was continued for 6 months. His hypomanic traits and psychogenic seizures progressively withdrew. The 6-month follow-up confirmed improvement of his psychiatric symptoms. His CBCL and MASC scores had decreased. Mazzone L, et al. Hypomanic mood in a child patient treated with interferon-alpha 2a: case report. Brain and Development 29: 666-669, No. 10, Nov 2007 - Italy 801097870 1 Reactions 8 Dec 2007 No. 1181 0114-9954/10/1181-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload
buidien
Category

Documents
view
218
download
1

Embed Size (px):

Transcript of Interferon-α-2a

Reactions 1181 - 8 Dec 2007

Interferon-α-2a

Hypomanic mood in a child: case reportA 10-year-old boy developed hypomanic mood while

receiving interferon-α-2a for chronic hepatitis B.The boy received SC interferon-α-2a at a dose of 3 MIU

three times weekly. About 30 days after the start of treatment,his parents noticed a change in his mood, with markedirritability and psychomotor agitation. He also showedexcessive involvement in activities with a high risk of painfulconsequences. He had episodes of staring, closed eyes, loss ofconsciousness, thrashing and chaotic jerky movements of histrunk, limbs and head. Each episode lasted for about10–20 minutes and recurred at intervals throughout the week.Postcritical arousal was slow and followed by irritability andheadache. He was hyperactive, distracted, excessivelytalkative and had a decreased need for sleep. A mental statusexamination showed inflated self-esteem, increased speechrhythm and racing thoughts. He had pathological total scoreson the Parent Child Behavior Checklist (CBCL) and theMultidimensional Anxiety Scale for Children (MASC).

The boy received risperidone and cognitive-behaviouraltreatment. Interferon-α-2a was continued for 6 months. Hishypomanic traits and psychogenic seizures progressivelywithdrew. The 6-month follow-up confirmed improvement ofhis psychiatric symptoms. His CBCL and MASC scores haddecreased.Mazzone L, et al. Hypomanic mood in a child patient treated with interferon-alpha2a: case report. Brain and Development 29: 666-669, No. 10, Nov 2007 -Italy 801097870